Sickle cell trait not linked to stroke in African-Americans

Sickle cell trait not linked to stroke in african-americans

(HealthDay)—For African-Americans, sickle cell trait (SCT) seems not to be associated with the incidence of ischemic stroke, according to a meta-analysis published online April 23 in JAMA Neurology.

Hyacinth I. Hyacinth, M.D., Ph.D., M.P.H., from Emory Children's Center in Atlanta, and colleagues conducted a to examine whether SCT is associated with increased risk of incident among African-Americans. Four prospective population-based studies with African-American cohorts were assessed, including 19,464 individuals (1,520 with SCT, 17,944 without SCT, and 620 with ischemic stroke).

The researchers found that the distribution of risk factors for ischemic stroke did not differ when they compared participants with versus those without SCT at study visit 1 in each cohort. The crude incidence of ischemic stroke was 2.9 and 3.2 per 1,000 person-years for those with and without SCT, respectively. In the meta-analysis of all four cohorts, the hazard ratio of incident ischemic stroke independently associated with SCT was 0.8 (95 percent confidence interval, 0.47 to 1.35; P = 0.82), after adjustment for . Similar results were obtained for the individual cohorts.

"The results of this study suggest performing a more thorough clinical evaluation of a stroke patient with SCT rather than assuming that SCT is the etiologic factor for the stroke," the authors write.

More information: Abstract/Full Text

Journal information: Archives of Neurology

Copyright © 2018 HealthDay. All rights reserved.

Citation: Sickle cell trait not linked to stroke in African-Americans (2018, April 27) retrieved 26 April 2024 from https://medicalxpress.com/news/2018-04-sickle-cell-trait-linked-african-americans.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Greater benefit for pioglitazone in high-risk patients post stroke

3 shares

Feedback to editors